Prescribed Medication for Acute Treatment for Migraine Market By Drug Type (Abortive and Prophylactic), By Route of Administration (Oral, Injectables and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)  and Geography (North America, Latin America, Europe, Asia Pacific and Middle East and Africa)  

Purchase Option

$ 4400
$ 6600
$ 8900

Prescribed Medication For Acute Treatment For Migraine Market size estimated to be valued at USD 2,587.9 million in 2022 and is poised to grow at a significant CAGR of 13.7% over 2023-2029. The market for prescribed medications for acute treatment of migraine is expected to offer lucrative opportunities for the market players due to the launch of novel molecules in the U.S. market. The companies have focused on novel therapeutics, an alternative to the triptan class of drugs due to the adverse effects like cardiovascular disorders, chest pressure, and others. Novel treatment options and increased prevalence of migraine are expected to drive the market. Increased awareness initiatives, the availability of research funds from private and public bodies, a development in the reimbursement scenario for associated medications, and increasing awareness about the effectiveness of such medicines are among the significant factors fuelling the market's growth. Furthermore, rising pharmaceutical R&D operating costs and rising healthcare spending are expected to drive the global prescribed medications for acute migraine treatment market growth rate during the forecast period. In the prescribed medications for acute treatment of migraine market, abortive prescribed medications for acute treatment of migraine accounted for a larger revenue share in 2021 and are projected to grow with a CAGR of 13.9% from 2022-2028 to reach US$ 1,653.7 Mn by 2028. However, the market for prophylactic drugs is anticipated to grow with a significant CAGR over the forecast years in prescribed medications for acute treatment of migraine.

Prescribed Medication For Acute Treatment For Migraine Market Key Developments:
  • In February 2022, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. It is recommended as the 75 mg dose of Rimegepant (available as an orally dissolving tablet) for marketing authorization for both the acute treatment of migraine with or without aura in adults and the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.
  • In January 2022, BioDelivery Sciences launched a new drug Elyxyb (celecoxib oral solution), a fast-acting liquid. It is one of the first Food and Drug Administration-approved ready-to-use oral solutions for adults in the acute treatment of migraine, with or without aura.

Global Prescribed Medication For Acute Treatment For Migrane Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

13.7%

Largest Market

North America

Fastest Growing Market

Europe
Prescribed Medication for Acute Treatment for Migraine Market Dynamics

The increasing awareness of novel drug classes and the rising incidence of migraine problems worldwide drive the target market's growth. Additionally, factors such as increasing work pressure, high alcohol consumption, growing demand for quality drugs, changes in lifestyles, and awareness among patients associated with the prevention and treatment of migraine further increase the demand levels for the global prescribed medications for acute treatment of migraine market. The increasing precedence of other therapies and side effects associated with migraine drugs limit the growth of the prescribed medications for acute migraine treatment market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
  • The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario.

Global Prescribed Medication For Acute Treatment For Migrane Market Segmentation

By Drug Type
  • Abortive
  • Prophylactic
By Route-administration
  • Oral
  • Injectables
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
By Geography
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

2022 is the base year and 2029 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Prescribed Medication For Acute Treatment For Migraine Market size estimated to be valued at USD 2,587.9 million in 2022 and is poised to grow at a significant CAGR of 13.7% over 2023-2029.

Europe is the fastest-growing for Prescribed Medication For Acute Treatment For Migraine Market.

1.Executive Summary
2.Global Prescribed Medication for Acute Treatment for Migraine Market Introduction 
2.1.Global Prescribed Medication for Acute Treatment for Migraine Market  - Taxonomy
2.2.Global Prescribed Medication for Acute Treatment for Migraine Market  - Definitions
2.2.1.Drug Type
2.2.2.Route-administration
2.2.3.Distribution Channel
2.2.4.Region
3.Global Prescribed Medication for Acute Treatment for Migraine Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Prescribed Medication for Acute Treatment for Migraine Market Analysis, 2018-2022 and Forecast 2023-2029
4.1.  Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Prescribed Medication for Acute Treatment for Migraine Market  By Drug Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Abortive
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Prophylactic
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6.Global Prescribed Medication for Acute Treatment for Migraine Market  By Route-administration, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Oral
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Injectables
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Others
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7.Global Prescribed Medication for Acute Treatment for Migraine Market  By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online Pharmacies
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Prescribed Medication for Acute Treatment for Migraine Market  By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Prescribed Medication for Acute Treatment for Migraine Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Drug Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Abortive
9.1.2.Prophylactic
9.2.  Route-administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Oral
9.2.2.Injectables
9.2.3.Others
9.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Online Pharmacies
9.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Prescribed Medication for Acute Treatment for Migraine Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Abortive
10.1.2.Prophylactic
10.2.  Route-administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Oral
10.2.2.Injectables
10.2.3.Others
10.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Online Pharmacies
10.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11.Asia Pacific (APAC) Prescribed Medication for Acute Treatment for Migraine Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Abortive
11.1.2.Prophylactic
11.2.  Route-administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Oral
11.2.2.Injectables
11.2.3.Others
11.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Online Pharmacies
11.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Prescribed Medication for Acute Treatment for Migraine Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Abortive
12.1.2.Prophylactic
12.2.  Route-administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Oral
12.2.2.Injectables
12.2.3.Others
12.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Online Pharmacies
12.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Prescribed Medication for Acute Treatment for Migraine Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Abortive
13.1.2.Prophylactic
13.2.  Route-administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Oral
13.2.2.Injectables
13.2.3.Others
13.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Online Pharmacies
13.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.AstraZeneca Plc.
14.2.2.Novartis AG
14.2.3.Merck & Co., Inc.
14.2.4.Pfizer, Inc.
14.2.5.Teva Pharmaceutical Industries Ltd.
14.2.6.Endo Pharmaceuticals Inc.
14.2.7.Avanir Pharmaceuticals, Inc.
14.2.8.Eli Lilly and Company
14.2.9.Biohaven Pharmaceutical Holding Co., Ltd
15. Research Methodology 
16. Appendix and Abbreviations 
  • AstraZeneca Plc.
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Endo Pharmaceuticals Inc.
  • Avanir Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Biohaven Pharmaceutical Holding Co., Ltd

Adjacent Markets